Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E. Ware, Robert J. Adams, Isaac Odame et al.|The Lancet|2015Cited by 518
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell AnemiaRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|Blood|2015Cited by 17
Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling ParametersKevin H.M. Kuo, Susan P. Perrine, Sylvia T. Singer et al.|Blood|2023Cited by 2